Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 … Read more
Jiangsu Recbio Technology Co., Ltd. (G93) - Total Liabilities
Latest total liabilities as of June 2025: €1.37 Billion EUR
Based on the latest financial reports, Jiangsu Recbio Technology Co., Ltd. (G93) has total liabilities worth €1.37 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Recbio Technology Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how Jiangsu Recbio Technology Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Recbio Technology Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Jiangsu Recbio Technology Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Surrozen Inc
NASDAQ:SRZN
|
USA | $117.56 Million |
|
Me2on Co. Ltd
KQ:201490
|
Korea | ₩52.04 Billion |
|
KPX Chemical
KO:025000
|
Korea | ₩195.44 Billion |
|
T'way Air Co Ltd
KO:091810
|
Korea | ₩1.74 Trillion |
|
Hot Chili Limited
OTCQX:HHLKF
|
USA | $5.17 Million |
|
Gogolook Co Ltd
TW:6902
|
Taiwan | NT$559.08 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Jiangsu Recbio Technology Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Recbio Technology Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Recbio Technology Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of Jiangsu Recbio Technology Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.41 Billion | +26.50% |
| 2023-12-31 | €1.12 Billion | +69.88% |
| 2022-12-31 | €656.53 Million | +166.96% |
| 2021-12-31 | €245.92 Million | -- |